Minerva Surgical Overview
Minerva Surgical (UTRS) has a ROE of -175.52%, below the Healthcare sector average of 20.77%.
Get informed when a big investor buys or sells
+ Follow-175.52%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Minerva Surgical (UTRS) currently reports a ROE of -175.52%. That is below the Healthcare sector average of 20.77%. Use the charts on this page to explore Minerva Surgical's ROE history and peer comparisons.
Minerva Surgical's ROE of -175.52% is lower than the Healthcare sector average of 20.77%. That is roughly 945.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Minerva Surgical's current -175.52% should be judged against Healthcare norms (sector average: 20.77%) and against UTRS's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -175.52%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 20.77%. From there, open related valuation or income-statement pages for Minerva Surgical, and consider following UTRS for alerts when major investors trade the stock.
Minerva Surgical is classified in the Healthcare sector. On ROE, it currently shows -175.52% versus a sector average near 20.77%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing UTRS with unrelated industries.
